TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05318443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP04
Description: SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Avastin, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.
Study: NCT01446003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8457
Description: 10 x 10-mg capsule BID for 10 days
Study: NCT05318443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.
Study: NCT00332566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib Kft vaccine GSK323527A
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB/Hiberix™
Description: Intramuscular injection, 1 dose
Study: NCT02632916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Intravenous zoledronic acid 0.025mg/kg at baseline, 6 months, 12 months and 18 months
Study: NCT03715829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Induction dose 1. Oral tablet taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Induction dose 1. Oral tablet taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Induction dose 1. Oral tablet taken QD
Study: NCT02632916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subcutaneous denosumab 1.0mg/kg at baseline, 6 months, 12 months and 18 months
Study: NCT02684084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex
Description: OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex
Description: OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
Study: NCT01095718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Errorless Learning
Description: Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modeling
Description: The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trial and Error
Description: The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps.
Study: NCT02165423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myFAMI iPad application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myFAMI iPad application
Study: NCT02621788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training for Residents (SMART-R)
Description: The SMART-R is a mind-body Educational Program for residents that is aimed at reducing the impact of stress and enhancing coping strategies through skill building exercises. The intervention consists of 3, 2 hour sessions over the course of 12 months.
Study: NCT01423357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Condom distribution and peer education
Description: Condom distribution and condom demonstrations by youth peer educators at least twice a week
Study: NCT00430677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisone or prednisolone)
Description: tablets, oral, 0.5-0.8 mg/kg, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisone or prednisolone)
Description: tablets, oral, 0.5-0.8 mg/kg, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisone or prednisolone)
Description: tablets, oral, 0.5-0.8 mg/kg, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: intravenous solution, injectable, 30 mg/kg, every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: intravenous solution, injectable, 10 mg/kg, every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: tablets, oral, 1.5 to 2 g, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: tablets, oral, 1.5 to 2 g, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: tablets, oral, 1.5 to 2 g, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: intravenous solution, injectable, 10 mg/kg, every 28 days
Study: NCT02664636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: Occupational Therapy (days 0 to 60): Orthopaedic maintenance, exercises for sitting and standing balance, sensorimotor techniques for the restoration of motor skills, grip exercises. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. 1 session is performed per day.~This is part of routine care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy
Description: During the therapy protocol, cortical activation measures using the fNIRS method will be conducted every 15 days (at Day0, Day 15, Day 30, Day 45 and Day 60 for 5 sessions in total) at the technical platform of the Grau du Roi physical therapy centre, during the completion of a standardized motor task (maintaining a level of force) using the healthy upper limb and the paretic upper limb.
Study: NCT01796353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sexual rehabilitation
Description: exercise plus psycho-education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: usual care
Study: NCT03035409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin Hydrochloride
Description: Given PO
Study: NCT03466320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2
Description: This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2
Description: This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
Study: NCT03035409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Undergo nutritional counseling
Study: NCT03035409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00907868

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: partial breast irradiation
Description: Patients undergo radiation tumor bed boost
Study: NCT03466320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2
Description: This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
Study: NCT00907868

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole breast irradiation
Description: Patients undergo whole breast irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole breast irradiation
Description: Patients undergo whole breast irradiation
Study: NCT01456260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
Study: NCT01456260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
Study: NCT01691612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: installation of D. pteronyssinus allergens
Description: We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
Study: NCT03245437

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxytocin nasal spray
Description: nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: nasal spray

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition Skills Training
Description: Group based training in social cognition skills

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Social Cognition Skills Training
Description: Group based training in social cognition skills

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Management
Description: Group-based training in mental health management

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Management
Description: Group-based training in mental health management

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: placebo condition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: placebo condition
Study: NCT01257646

Intervention type: OTHER
Intervention: Gait analysis
Description: A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
Study: NCT01532973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched placebo tablets were administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched placebo tablets were administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched placebo tablets were administered orally.
Study: NCT01879605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate natrium and sorbitol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Study: NCT01532973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched placebo tablets were administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched placebo tablets were administered orally.
Study: NCT02096393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Patient specific instruments
Description: A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
Study: NCT02096393

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard instrumentation
Description: Standard instrumentation will be used during total knee replacement surgery.
Study: NCT01532973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched placebo tablets were administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched placebo tablets were administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched placebo tablets were administered orally.
Study: NCT02745210

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 13C magnetic resonance spectroscopy
Description: acquisition of 13C MR spectroscopy in the brain
Study: NCT02312271

Intervention type: OTHER
Intervention: enteral formula
Description: standard tube feeding formulas
Study: NCT00003350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT00434850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Pancreatic Islet Cells
Description: Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxyspergualin
Description: An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daclizumab or basiliximab
Description: Will replace antithymocyte globulin in all islet transplantations after the first one
Study: NCT03715829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Induction dose 2. Oral tablet taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance dose A. Oral tablet taken QD
Study: NCT00003350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00434850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Maintenance immunosuppressive therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Maintenance immunosuppressive therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Blocks TNF-alpha which is toxic to islet cells
Study: NCT01757704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open pleurae & conventional filling of heart
Description: After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intact pleurae & staged filling of heart
Description: After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
Study: NCT04212793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Fluorescence Endoscopy platform
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Fluorescence Endoscopy platform
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Fluorescence Endoscopy platform
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal
Study: NCT04040712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor FMT
Description: Fecal microbiota transplantation using stools from healthy donors

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham FMT
Description: Sham fecal microbiota transplantation
Study: NCT02890199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposomal